Oncorena AB, a Sweden-absed company that develops a new and potentially ground-breaking treatment for patients with advanced kidney cancer, announced on Monday that it has named Professor Borje Haraldsson as its new CEO.
Haraldsson is to succeed Dr Lars Grundemar, who will leave the company.
The company said that professor Haraldsson, one of the founders of Oncorena, has played a crucial role in the development of the company's drug candidate orellanine and is considered a world leader in clinical and experimental renal research. He has been serving as chief scientific officer and part of the firm's management team. He has held a management position at Novartis in Basel, Switzerland.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer